CRISPR removes HIV in animals

CRISPR-for-HIV is one of those ideas that sounds almost too clean. HIV hides by stitching its DNA into human cells. So the dream is simple to say — go in, cut that viral DNA back out, and the infection is gone. The news is that researchers really have done versions of that in animals. But the part getting lost online is just as important: the best animal results are still partial, and the first human trial has not shown a cure. ### What is CRISPR trying to do here? HIV’s hardest trick is latency. Even when antiretroviral therapy drives virus in the blood down to undetectable levels, HIV can sit quietly inside long-lived cells and tissues. That hidden reservoir is why people usually need lifelong treatment. CRISPR is being used as molecular scissors — programmed to recognize HIV sequences and cut them out of the host genome. The whole point is not just suppression, but removal. (medicine.temple.edu) ### What actually worked in animals? The cleanest proof-of-concept came in humanized mice first, then in non-human primates with an HIV-like virus called SIV. Temple and University of Nebraska teams showed that a sequential strategy — long-acting ART first, then CRISPR-Cas9 aimed at viral DNA — could eliminate detectable repli(medicine.temple.edu)om viral reservoirs across tissues without detected off-target effects in that study. (scholarshare.temple.edu) ### So did the animals get cured? Some did in the mouse studies, but not consistently enough to call the problem solved. The key follow-up from 2025 is easy to miss because it is less splashy than the original headlines: researchers looked at the animals that rebounded after the dual treatment and found that viral rebound still happened in more than half of the dual-treated humanized mice. That means the result is real proof-of-concept, but not durable clearance across the board. (nature.com) ### Why is rebound such a big deal? Because rebound is the whole game. HIV can look gone if blood tests are quiet for a while, then come roaring back from a tiny reservoir. Think of it less like killing weeds and more like pulling roots — if even a few roots stay in the ground, the garden fills back in. A cure strategy has to show that the virus does not return after treatment stops. That is why “some animals had no re(nature.com)uth. (nature.com) ### Was CRISPR causing escape mutants? Turns out that was one of the big worries, and the 2025 rebound-paper result was a bit reassuring. The rebound viruses mostly looked like accelerated drug-resistance escape under ART pressure, not obvious CRISPR-specific mutant escape. That does not remove the delivery problem, but it suggests CRISPR itself was not the main driver of the rebound signatures they saw. (nature.com)pened in people? The first-in-human program is Excision BioTherapeutics’ EBT-101 trial. Early data showed the treatment was generally tolerated, but when participants interrupted ART, the first reported cases still had viral rebound rather than sustained remission. One participant had delayed rebound for about 4 months, which is interesting, but that is not a cure. The trial itself remains an early-stage safety-focused study. (aidsmap.com) ### So why are scientists still excited? Because this moved the field past theory. Researchers have now shown in living animals that CRISPR can reach viral reservoirs and cut integrated HIV-like DNA. That is a real step. But the bottleneck has shifted — from “can the scissors cut?” to “can enough edited cells be reached, across enough tissues, to stop rebound every time?” (medicine.temple.edu) ### Bottom line? This is not “HIV cured by CRISPR.” It is “CRISPR can remove HIV-like viral DNA in animals, sometimes deeply enough to prevent rebound — but not reliably yet.” That is still important. It means the idea is biologically real. The catch is that biology only counts it as a cure when the virus stays gone. (nature.com)